10 completed. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 10 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 866 | 2025-03-11 | 2026-09-28 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 818 | 2024-06-26 | 2026-10-14 |
| Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia | Phase 3 | Completed | LG Chem | 2202 | 2023-03-30 | 2025-07-22 |
| Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Tigulixostat, Placebo - Gout, Hyperuricemia | Phase 3 | Completed | LG Chem | 354 | 2022-10-25 | 2025-10-29 |
| Prednisone for Heart Failure Patients With Hyperuricemia Prednisone, Allopurinol - Heart Failure, Hyperuricemia | Phase 2 / Phase 3 | Completed | Hebei Medical University | 205 | 2013-12-01 | 2018-10-16 |
| Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Febuxostat, Allopurinol - Cardiovascular Disease | Phase 3 | Completed | Takeda | 6198 | 2010-04-23 | 2018-06-14 |
| Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia TULY - Hyperuricemia | Phase 3 | Completed | Virchow Group | 100 | 2010-02-01 | 2014-12-12 |
| Efficacy and Safety of Oral Febuxostat in Participants With Gout Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Takeda | 2269 | 2007-02-01 | 2012-02-02 |
| Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Rasburicase (SR29142), Allopurinol - Tumor Lysis Syndrome, Cancer | Phase 3 | Completed | Sanofi | 280 | 2004-04-01 | 2010-01-12 |
| Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Takeda | 1086 | 2003-07-01 | 2010-07-27 |
Gout (6) · Arthritis, Gouty (2) · Cardiovascular Diseases (1) · Heart Failure (1) · Leukemia (1) · Lymphoma (1) · Myelodysplastic Syndromes (1) · Myocardial Infarction (1) · Neoplasms (1) · Stroke (1) · Tumor Lysis Syndrome (1)
Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Arthritis (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Crystal Arthropathies (6) · Genetic Diseases, Inborn (6) · Joint Diseases (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Musculoskeletal Diseases (6) · Nutritional and Metabolic Diseases (6) · Purine-Pyrimidine Metabolism, Inborn Errors (6) · Rheumatic Diseases (6) · Heart Diseases (2) · Bone Marrow Diseases (1)
Allopurinol (6) · Febuxostat (3) · Prednisone (1) · Urate Oxidase (1) · rasburicase (1)
Takeda (3) · Arthrosi Therapeutics (2) · LG Chem (2) · Hebei Medical University (1) · Sanofi (1) · Virchow Group (1)
United States (7) · Australia (2) · Georgia (2) · New Zealand (2) · Philippines (2) · Taiwan (2) · Thailand (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · China (1) · Colombia (1) · Czechia (1) · France (1)
Hyungjin Cho, MD (2) · Robert Keenan, MD (2) · Dr. Raghunadharao D (1)
PMID 39929260, PMID 19286847, PMID 20370912, PMID 21353107, PMID 21849262, PMID 22052584, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22795277, PMID 23683134, PMID 29527974, PMID 35536764